BIOMARKERS FOR RESPONSE TO TYROSINE KINASE PATHWAY INHIBITORS IN CANCER
First Claim
Patent Images
1. A method of treating a cancer patient comprising:
- (a) selecting a patient determined to have a cancer with an elevated KDR, PDGFR, or KIT level; and
(b) treating the patient with a VEGF/VEGFR, PDGFR, or KIT pathway inhibitor.
1 Assignment
0 Petitions
Accused Products
Abstract
Copy number gains detected in tumors and associated with drug sensitivity and resistance in vivo and in vitro can be used as biomarkers to select, predict and monitor drug treatment outcomes in cancer patients treated with tyrosine kinase inhibitors. Methods to identify patients with NSCLC or other malignancies who are more likely to benefit from tyrosine kinase inhibitors such as VEGF or VEGFR inhibitors when used either as monotherapy or in combination with other therapies such as chemotherapy or EGFR inhibitors, and who are in the advanced stages of disease and/or who have undergone adjuvant therapy are also provided herein.
-
Citations
47 Claims
-
1. A method of treating a cancer patient comprising:
-
(a) selecting a patient determined to have a cancer with an elevated KDR, PDGFR, or KIT level; and (b) treating the patient with a VEGF/VEGFR, PDGFR, or KIT pathway inhibitor. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 46)
-
-
15. A method of predicting sensitivity of a cancer in a patient to VEGF/VEGFR, PDGFR, or KIT pathway inhibitors comprising:
-
(a) obtaining a sample of the cancer; and (b) determining the KDR, PDGFR, and KIT level in the sample, wherein if the KDR, PDGFR, or KIT level is elevated, then the cancer is predicted to be sensitive to VEGF/VEGFR, PDGFR, or KIT pathway inhibitors. - View Dependent Claims (40)
-
-
16-28. -28. (canceled)
-
29. A method of predicting sensitivity of a cancer in a patient to EGFR inhibitors or platinum-based chemotherapy comprising:
-
(a) obtaining a sample of the cancer; and (b) determining the KDR level in the sample, wherein if the KDR level is not elevated, then the cancer is predicted to be sensitive to EGFR inhibitors or platinum-based chemotherapy.
-
-
30-39. -39. (canceled)
-
41-42. -42. (canceled)
-
43. A method of determining a prognosis of a cancer patient comprising:
-
(a) obtaining a sample of the patient'"'"'s cancer; and (b) detecting polymorphisms at nucleotides−
37 and 1416 in the KDR gene in the cells comprising the sample, wherein the cancer is determined to have a better prognosis if the −
37 AG/GG and (or?) 1416 AT/TT polymorphisms are present. - View Dependent Claims (44)
-
-
45. (canceled)
-
47-48. -48. (canceled)
Specification